Until now, no molecular-targeted agents have been approved for pancreatic cancer treatment, except poly ADP ribose polymerase (PARP) inhibitors, which are effective for pancreatic cancer with BRCA1/2 germline mutations (8). This evidence concerns the gene BRCA1 and pancreatic neoplasm.